Niagen Bioscience
Niagen Bioscience (NASDAQ: NAGE) is a publicly traded Consumer Longevity company founded in 1999 and based in Los Angeles, United States.
Niagen Bioscience is the Los Angeles company formerly known as ChromaDex, which renamed itself and adopted the Nasdaq ticker NAGE effective March 19, 2025 to focus on healthy aging and NAD+ science. Founded in 1999 by Frank Jaksch, it commercializes Niagen, a patented form of nicotinamide riboside that serves as an NAD+ precursor, sold direct-to-consumer as Tru Niagen, which it positions as the leading NAD+ supplement in the United States. The company also licenses its NAD+ ingredients and operates an analytical-reference-standards and ingredients business serving the broader supplement industry.
A rare public pure-play on NAD+ supplementation, supplying both a consumer brand and the underlying ingredient used across the longevity supplement market.
niagenbioscience.com ↗·Consumer Longevity·
United States·public · NASDAQ: NAGE 
